Paula Rodríguez Otero, MD, on Updated Ide-Cel Data From KarMMa-3 Analysis

Paula Rodríguez Otero, MD, from the University of Navarra in Pamplona, Spain, described the updated analysis of the KarMMa-3 trial presented at the 65th American Society of Hematology Annual Meeting & Exposition for Blood Cancers Today.

“This randomized study evaluated idecabtagene vicleucel or ‘ide-cel’ versus standard regimens in a population of patients with triple-class exposed disease and relapsed refractory multiple myeloma.”

Dr. Otero noted that the ide-cel continued to show significant improvements over standard regimens over a median follow-up of 30.9 months with a median progression-free survival of 13.8 months versus 4.4 months, respectively, and a hazard ratio of 0.49.

“We believe that this longer follow-up in the the KarMMa-3 study continues to demonstrate a significantly longer and clinically meaningful improvement in progression free survival with ide-cel versus standard regimens in patients with triple-class exposed and early-line relapse,” Dr. Otero explained.

Dr. Otero also explained that overall survival results were comparable between the arms due to a significant amount of standard regimen patients crossing over to receive ide-cel therapy. She added that analyses adjusted for crossover showed an improvement in overall survival favoring ide-cel.

Dr. Otero also highlighted an analysis focused on health-related quality of life that suggested “patients treated with ide-cel showed a significant and meaningful improvement in myeloma-related symptoms, functioning, and overall health status compared with the standard regimens arm.”